Caplin Point Laboratories Resultados de beneficios anteriores
Pasado controles de criterios 4/6
Caplin Point Laboratories ha aumentado sus beneficios a una tasa media anual de 18.7%, mientras que los beneficios de la industria de Pharmaceuticals han experimentado un crecimiento de 14.8% anual. Los ingresos han ido creciendo a una tasa media de 18.3% al año. La rentabilidad financiera de Caplin Point Laboratories es de 21%, y sus márgenes netos son de 26.8%.
Información clave
18.8%
Tasa de crecimiento de los beneficios
18.7%
Tasa de crecimiento del BPA
| Crecimiento de la industria Pharmaceuticals | 17.5% |
| Tasa de crecimiento de los ingresos | 17.5% |
| Rentabilidad financiera | 19.7% |
| Margen neto | 27.0% |
| Última actualización de beneficios | 31 Mar 2024 |
Actualizaciones de resultados anteriores recientes
Recent updates
Caplin Point Laboratories (NSE:CAPLIPOINT) Strong Profits May Be Masking Some Underlying Issues
May 24
Does Caplin Point Laboratories (NSE:CAPLIPOINT) Deserve A Spot On Your Watchlist?
May 04Caplin Point Laboratories Limited's (NSE:CAPLIPOINT) Low P/E No Reason For Excitement
Mar 07With EPS Growth And More, Caplin Point Laboratories (NSE:CAPLIPOINT) Makes An Interesting Case
Oct 24Why We Think The CEO Of Caplin Point Laboratories Limited (NSE:CAPLIPOINT) May Soon See A Pay Rise
Sep 15Caplin Point Laboratories (NSE:CAPLIPOINT) Will Pay A Larger Dividend Than Last Year At ₹2.50
Aug 11We Discuss Whether Caplin Point Laboratories Limited's (NSE:CAPLIPOINT) CEO Is Due For A Pay Rise
Sep 23Caplin Point Laboratories' (NSE:CAPLIPOINT) Shareholders Will Receive A Bigger Dividend Than Last Year
Sep 11Is Now The Time To Put Caplin Point Laboratories (NSE:CAPLIPOINT) On Your Watchlist?
Jul 22Caplin Point Laboratories (NSE:CAPLIPOINT) Is Increasing Its Dividend To ₹2.00
May 15A Look At The Intrinsic Value Of Caplin Point Laboratories Limited (NSE:CAPLIPOINT)
Jan 21Should You Be Adding Caplin Point Laboratories (NSE:CAPLIPOINT) To Your Watchlist Today?
Oct 20Caplin Point Laboratories (NSE:CAPLIPOINT) Is Increasing Its Dividend To ₹1.50
Sep 17Caplin Point Laboratories (NSE:CAPLIPOINT) Will Pay A Larger Dividend Than Last Year At ₹1.50
Sep 03Caplin Point Laboratories Limited's (NSE:CAPLIPOINT) Intrinsic Value Is Potentially 28% Above Its Share Price
Aug 27Is Caplin Point Laboratories (NSE:CAPLIPOINT) A Risky Investment?
Jun 12Estimating The Fair Value Of Caplin Point Laboratories Limited (NSE:CAPLIPOINT)
Apr 29Does Caplin Point Laboratories Limited (NSE:CAPLIPOINT) Have A Place In Your Dividend Portfolio?
Mar 24We Think Caplin Point Laboratories (NSE:CAPLIPOINT) Can Stay On Top Of Its Debt
Mar 11Do Caplin Point Laboratories's (NSE:CAPLIPOINT) Earnings Warrant Your Attention?
Feb 26What We Learned About Caplin Point Laboratories' (NSE:CAPLIPOINT) CEO Pay
Feb 14Caplin Point Laboratories Limited's (NSE:CAPLIPOINT) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?
Feb 02Can You Imagine How Jubilant Caplin Point Laboratories' (NSE:CAPLIPOINT) Shareholders Feel About Its 105% Share Price Gain?
Jan 21
Does This Valuation Of Caplin Point Laboratories Limited (NSE:CAPLIPOINT) Imply Investors Are Overpaying?
Jan 09Could The Caplin Point Laboratories Limited (NSE:CAPLIPOINT) Ownership Structure Tell Us Something Useful?
Dec 28Is It Worth Buying Caplin Point Laboratories Limited (NSE:CAPLIPOINT) For Its 0.5% Dividend Yield?
Dec 16We Think Caplin Point Laboratories (NSE:CAPLIPOINT) Can Stay On Top Of Its Debt
Dec 04Should You Be Adding Caplin Point Laboratories (NSE:CAPLIPOINT) To Your Watchlist Today?
Nov 21Here's What We Learned About The CEO Pay At Caplin Point Laboratories Limited (NSE:CAPLIPOINT)
Nov 08Desglose de ingresos y gastos
Cómo gana y gasta dinero Caplin Point Laboratories. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).
Historial de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Gastos G+A | Gastos de I+D |
|---|---|---|---|---|
| 31 Mar 24 | 16,941 | 4,571 | 1,436 | 0 |
| 31 Dec 23 | 16,318 | 4,376 | 1,430 | 632 |
| 30 Sep 23 | 15,683 | 4,179 | 1,408 | 632 |
| 30 Jun 23 | 15,157 | 3,947 | 1,396 | 0 |
| 31 Mar 23 | 14,683 | 3,763 | 1,371 | 632 |
| 31 Dec 22 | 14,182 | 3,532 | 1,314 | 593 |
| 30 Sep 22 | 13,724 | 3,307 | 1,262 | 593 |
| 30 Jun 22 | 13,153 | 3,140 | 1,210 | 0 |
| 31 Mar 22 | 12,710 | 2,998 | 1,154 | 593 |
| 31 Dec 21 | 12,099 | 2,872 | 1,110 | 537 |
| 30 Sep 21 | 11,581 | 2,767 | 1,071 | 537 |
| 30 Jun 21 | 11,217 | 2,586 | 1,034 | 0 |
| 31 Mar 21 | 10,624 | 2,423 | 1,026 | 537 |
| 31 Dec 20 | 9,986 | 2,248 | 952 | 530 |
| 30 Sep 20 | 9,524 | 2,189 | 874 | 530 |
| 30 Jun 20 | 9,107 | 2,193 | 780 | 0 |
| 31 Mar 20 | 8,640 | 2,150 | 678 | 530 |
| 31 Dec 19 | 8,356 | 2,159 | 617 | 282 |
| 30 Sep 19 | 7,664 | 2,032 | 557 | 282 |
| 30 Jun 19 | 6,948 | 1,894 | 512 | 0 |
| 31 Mar 19 | 6,490 | 1,766 | 471 | 282 |
| 31 Dec 18 | 6,048 | 1,621 | 449 | 237 |
| 30 Sep 18 | 5,874 | 1,538 | 431 | 237 |
| 30 Jun 18 | 5,628 | 1,459 | 417 | 0 |
| 31 Mar 18 | 5,399 | 1,448 | 391 | 237 |
| 31 Dec 17 | 5,145 | 1,430 | 367 | 141 |
| 30 Sep 17 | 4,757 | 1,297 | 352 | 141 |
| 30 Jun 17 | 4,401 | 1,165 | 322 | 0 |
| 31 Mar 17 | 4,016 | 956 | 321 | 141 |
| 31 Dec 16 | 3,655 | 783 | 300 | 54 |
| 30 Sep 16 | 3,420 | 703 | 274 | 54 |
| 30 Jun 16 | 3,238 | 619 | 258 | 54 |
| 31 Mar 16 | 3,088 | 584 | 240 | 54 |
| 31 Dec 15 | 2,906 | 535 | 298 | 67 |
| 30 Sep 15 | 2,722 | 465 | 283 | 60 |
| 30 Jun 15 | 2,518 | 410 | 203 | 59 |
| 31 Mar 15 | 2,296 | 353 | 233 | 53 |
| 31 Dec 14 | 2,074 | 318 | 220 | 42 |
| 30 Sep 14 | 1,893 | 305 | 204 | 33 |
| 30 Jun 14 | 1,731 | 258 | 190 | 21 |
| 31 Mar 14 | 1,643 | 204 | 166 | 4 |
| 31 Dec 13 | 1,517 | 167 | 149 | 0 |
| 30 Sep 13 | 1,408 | 125 | 137 | 0 |
| 30 Jun 13 | 1,270 | 140 | 125 | 7 |
Ingresos de calidad: CAPLIPOINT tiene un alto nivel de ganancias no monetarias.
Margen de beneficios creciente: Los actuales márgenes de beneficio (26.8%) de CAPLIPOINT son superiores a los del año pasado (24.9%).
Análisis del flujo de caja libre vs. Beneficios
Análisis del crecimiento de los beneficios en el pasado
Tendencia de beneficios: Los beneficios de CAPLIPOINT han crecido un 18.7% al año en los últimos 5 años.
Acelerando crecimiento: El crecimiento de los beneficios de CAPLIPOINT en el último año (23.9%) supera su media de 5 años (18.7% al año).
Beneficios vs. Industria: El crecimiento de los beneficios de CAPLIPOINT en el último año (21.5%) superó al de la industria Pharmaceuticals 20.3%.
Rentabilidad financiera
Alta ROE: La rentabilidad financiera de CAPLIPOINT (19.7%) se considera baja.